ORIGINAL RESEARCH

Bilirubin Nanoparticles Protect Against Cardiac Ischemia/Reperfusion Injury in Mice

Wen Ai, MD; Soochan Bae, PhD; Qingen Ke, MD; Shi Su, BS; Ruijian Li, MD; Yanwei Chen, MD; Dohyun Yoo, PhD; Eesac Lee, BS; Sangyong Jon, PhD; Peter M. Kang, MD

BACKGROUND: Ischemia/reperfusion (I/R) injury causes overproduction of reactive oxygen species, which are the major culprits of oxidative stress that leads to inflammation, apoptosis, myocardial damage, and dysfunction. Bilirubin acts as a potent endogenous antioxidant that is capable of scavenging various reactive oxygen species. We have previously generated bilirubin nanoparticles (BRNPs) consisting of polyethylene glycol–conjugated bilirubin. In this study, we examined the therapeutic effects of BRNPs on myocardial I/R injury in mice.

METHODS AND RESULTS: In vivo imaging using fluorophore encapsulated BRNPs showed BRNPs preferentially targeted to the site of I/R injury in the heart. Cardiac I/R surgery was performed by first ligating the left anterior descending coronary artery. After 45 minutes, reperfusion was achieved by releasing the ligation. BRNPs were administered intraperitoneally at 5 minutes before and 24 hours after reperfusion. Mice that received BRNPs showed significant improvements in their cardiac output, assessed by echocardiogram and pressure volume loop measurements, compared with the ones that received vehicle treatment. BRNPs treatment also significantly reduced the myocardial infarct size in mice that underwent cardiac I/R, compared with the vehicle-treatment group. In addition, BRNPs effectively suppressed reactive oxygen species and proinflammatory factor levels, as well as the amount of cardiac apoptosis.

CONCLUSIONS: Taken together, BRNPs could exert their therapeutic effects on cardiac I/R injury through attenuation of oxidative stress, apoptosis, and inflammation, providing a novel therapeutic modality for myocardial I/R injury.

Key Words: apoptosis ■ bilirubin nanoparticles ■ inflammation ■ ischemia reperfusion injury ■ reactive oxygen species

Early revascularization therapy via thrombolysis or percutaneous coronary intervention after myocardial infarction has significantly improved the mortality and morbidity of patients. However, ischemia/reperfusion (I/R) injury reduces the benefit of early revascularization therapy.1,2 Myocardial I/R injury is associated with excessive reactive oxygen species (ROS) production, which contributes to myocyte apoptosis and inflammation, and ultimately leads to myocardial damage and dysfunction.3,4 Therefore, ROS can be an attractive target for therapeutic intervention in myocardial infarction. Reducing ROS levels using an antioxidant has been proposed as a therapeutic strategy.5 Various antioxidants have been investigated as therapeutic strategies to reduce the deleterious effects of excessive ROS.6–8 However, the clinical application of antioxidant therapy for myocardial I/R injury remains a challenge.

Bilirubin is an endogenous antioxidant that scavenges various ROS. It has been shown to be a biomarker of cardiovascular health, and is inversely associated with the severity of cardiovascular diseases9,10 and all-cause mortality11 in the general population. Reduced risk of ischemic heart disease has been observed in Gunn rats, a mutant rat model with elevated bilirubin levels.12–14 The beneficial effects of bilirubin may be because of their antioxidative properties12,13,15,16 Studies using the Langendorff heart
perfusion approach to establish global cardiac ischemia models have demonstrated that bilirubin treatment may be protective against cardiac ischemia reperfusion injury. Particularly, administration of bilirubin dilaurate before or after global ischemia showed greater protection after ischemia.

To improve the solubility of bilirubin, we have previously developed bilirubin nanoparticles (BRNPs) using polyethylene glycol-modified bilirubin. We showed that BRNPs could be a simple and safe alternative to the parent bilirubin to effectively boost serum bilirubin concentrations without causing jaundice. In a hepatic I/R injury mouse model, BRNPs preconditioning exerted protective effects against hepatocellular injury. However, the effects of BRNPs on cardiac I/R models have not been reported. In this study, we investigated the potential therapeutic effects of BRNPs in a mouse model of cardiac I/R injury.

**METHODS**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Animal Model**

C57BL/6 mice (8–10 weeks old, both male and female) (Charles River Laboratory, Wilmington, MA) underwent cardiac I/R surgery as previously described. Briefly, mice were anesthetized with 2% inhalant isoflurane, intubated, and placed on a rodent ventilator (model 687; Harvard Apparatus). Meloxicam SR (4.0 mg/kg, ≈50 µL volume) was given subcutaneously once just before the procedure for pain control for all animals undergoing surgery. After thoracotomy, the left anterior descending artery was ligated with a 7-0 surgical silk suture tied around a specialized 30-gauge catheter. After 45 minutes, reperfusion was achieved by releasing the ligation. Sham-operated mice underwent the same procedure but without left anterior descending artery ligation or reperfusion.

BRNPs were prepared from polyethylene glycol–modified bilirubin by using a film formation and rehydration method as previously described. Stock solution of BRNPs was prepared by dissolving BRNPs in PBS at a concentration of 1 mg BRNPs/1 mL PBS. BRNPs were administered intraperitoneally at 2 time points, once at 5 minutes before and once at 24 hours after reperfusion. Tissues were collected at 24 hours after surgery to assess the markers for apoptosis, ROS, and inflammation. Cardiac functions were measured at 2 weeks after surgery. The animal care standards were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and all experimental procedures were approved by the Institutional Animal Care and Use Committee of Beth Israel Deaconess Medical Center.

**In Vivo and Ex Vivo Fluorescence Imaging and Biodistribution Assay**

In vivo and ex vivo fluorescence imaging was performed using a near-infrared imaging system. To assess the biodistribution of BRNPs, indocyanine green (ICG), a widely used near-infrared fluorophore, was encapsulated in BRNPs (BRNP-ICGs), and the complex was intravenously administered in mice via tail vein injection. One hour after administration, mice were euthanized, and the hearts, lungs, livers, and kidneys were collected for in vivo and ex vivo imaging. The biodistribution of BRNP-ICGs was assessed using a near-infrared imaging system. The heart, lungs, liver, and kidneys were excised, and the tissues were imaged to determine the fluorescence intensity. The results demonstrated that BRNP-ICGs accumulated in the myocardium, lungs, liver, and kidneys, indicating a high biodistribution in these organs.
were harvested. Tissues were washed with PBS before imaging. For the in vivo near-infrared imaging, mice were first anesthetized by intraperitoneal injection of ketamine/xylazine solution. The animals were then placed in supine position and underwent cardiac I/R procedure with BRNP-ICGs being administered intravenously upon initiating reperfusion.

**Cardiac Functional Analysis**

Cardiac function was measured by echocardiography and pressure-volume (PV) loop 2 weeks after cardiac I/R as previously described. Using a high-resolution small-animal echocardiogram (Vevo2100; Visual Sonics, Toronto, Canada) with an MS400 (18–36 MHz) transducer, 2-dimensional guided M-mode echocardiography was performed to assess anterior and posterior wall thickness, left ventricle (LV) dimensions, ejection fraction, and fractional shortening. Echocardiography was performed at baseline and 2 weeks after cardiac I/R.

The PV loop parameters were measured using a 1.4F microtip, pressure-volume catheter (Scisense, Ontario, Canada). While the mouse was anesthetized at 2% isoflurane, the catheter was inserted into the LV via the right common carotid artery to obtain LV hemodynamic parameters. Data were recorded using Powerlab (AD Instruments, Colorado Springs, CO). Beat-by-beat PV parameters including heart rate, stroke work, LV systolic contractility, LV diastolic relaxation, and cardiac output were measured and analyzed using CardioSoft Pro software (CardioSoft, Houston, TX).

**Infarct Size Measurement**

Myocardial infarct size was measured as previously described. After thoracotomy, the left anterior descending artery was ligated, and 50 μL of green fluorescent FluoSpheres (Molecular Probe, Carlsbad, CA) were injected into the LV of the heart to delineate the area at risk (FluoSpheres-negative area). After 24 hours, excised heart sections were incubated in TUNEL reaction mixture at 37 °C for 60 minutes. The percentage of TUNEL-positive cells was calculated by the ratio of stained TUNEL-positive (apoptotic) cells to the total number of cells. Cell nuclei were then counterstained with 4',6-diamidino-2-phenylindole. Images of the sections were acquired using confocal microscopy.

**Reverse Transcriptase-Polymerase Chain Reaction Analysis for mRNA Expression**

Twenty-four hours after cardiac I/R, heart tissues of the mice were collected for molecular analyses. Reverse transcriptase-polymerase chain reaction was performed as previously described. 18S ribosomal RNA primer was used as an internal control. All reverse transcriptase-polymerase chain reaction signals were normalized to the 18S ribosomal RNA signal of the corresponding reverse transcriptase products to eliminate the measurement error from uneven sample loading and to provide a semiquantitative measure of the relative changes in gene expression.

**RESULTS**

**Targeting of BRNPs to the I/R Injury Site in the Heart**

A schematic illustration of the preparation of BRNPs is shown in Figure 1A. Using a film formation and subsequent rehydration process in aqueous medium, polyethylene glycol-modified bilirubin self-assembles into BRNPs at an average size of ≈100 nm. We have shown in our previous reports that BRNPs possess high colloidal stability under physiological conditions and can circulate in the bloodstream with a half-life of...
≈6 hours, suggesting dramatic increase in its overall therapeutic effect compared with the parent bilirubin.\(^{18,23}\) To analyze the biodistribution of BRNPs, ICG-encapsulated BRNPs (BRNP-ICGs) were administered intravenously. To determine the optimal concentration of BRNP-ICGs for the near-infrared imaging system, we compared the image of 20 µg/mL and 200 µg/mL BRNP-ICGs. Scale bar=2 mm. C, Biodistribution of BRNP-ICGs after intravenous administration in the heart, lung, liver, and kidney with (top panel) or without (bottom panel) cardiac I/R surgery. Scale bar=1 mm. D, Time-lapse imaging showing the accumulation of BRNP-ICGs in the heart after cardiac I/R surgery. Scale bar=1 mm.

BRNPs Attenuated I/R-Induced Cardiac Dysfunction

Reperfusion of the ischemic myocardium triggers an overproduction of ROS, causing myocardial damage...
and cardiac dysfunction. Our previous studies showed that the cardiac functions of the mice were decreased 2 weeks after I/R injury. To examine the potential beneficial effect of BRNPs after cardiac I/R, we first performed pathologic analysis 2 weeks after I/R surgery. No mouse died after I/R injury in either the vehicle- or BRNPs-treated (2 doses: 10 and 30 mg/kg) group in this study. In the vehicle-treated group, there was a significant increase in both heart weight/body weight and lung weight/body weight ratios, which are indirect assessments of left and right heart failure, respectively (Figure 2A and 2B). However, mice treated with 30 mg/kg of BRNPs showed no significant increase in heart weight/body weight or lung weight/body weight ratios compared with the vehicle-treated mice after I/R surgery.

We further evaluated the cardiac functions of the mice 2 weeks after cardiac I/R injury using echocardiography and PV loop analysis. Sham-operated animals treated with BRNPs did not show significant changes in cardiac function. Cardiac I/R injury led to a significant decrease in LV ejection fraction and fractional shortening measured by echocardiography in vehicle-treated mice compared with sham-operated mice (Figure 2C through 2E, Table S1). Mice treated with BRNPs demonstrated significant improvement in cardiac functions compared with vehicle-treated mice after I/R surgery. Moreover, the beneficial effect of BRNPs was dose dependent (Figure 2D and 2E).

To validate the echocardiography results, PV loop measurements were performed. Consistent with the echocardiogram findings, cardiac I/R injury led to a significant decrease in LV function, as demonstrated by significant decrease in cardiac output and stroke work compared with sham-operated mice (Figure 2F through 2H, Table S2). There was also a significant decrease in systolic contractility and stroke volume, which suggest a decrease in systolic function compared with

![Figure 2. Effect of bilirubin nanoparticles (BRNPs) on cardiac function 2 wk after cardiac ischemia/reperfusion (I/R) surgery. A and B, Heart weight (HW)/body weight (BW) ratios (A) and lung weight (LW)/BW ratio (B) 2 wk after cardiac I/R surgery. C, Representative 2-dimensional echocardiographic images after cardiac I/R with or without BRNPs treatment. D and E, Ejection fraction (EF) (D) and fractional shortening (FS) (E) after cardiac I/R with or without BRNPs treatment. F, Representative pressure-volume loop images after cardiac I/R with or without BRNPs treatment. G and H, Cardiac output (CO) (G) and stroke work (SW) (H) after cardiac I/R with or without BRNPs treatment. *P<0.05 vs sham, †P<0.05 vs PBS I/R; n=5 mice/group (2 female, 3 male) in the sham group, 7 mice/group (3 female, 4 male) in the I/R group. LVP indicates left ventricular pressure.](image-url)
sham-operated mice (Table S2). We observed modest decrease in diastolic relaxation, an indication of impaired diastolic function, but the findings were not significant. BRNPs-treated mice showed significant improvement in cardiac output and stroke work compared with vehicle treated mice after cardiac I/R surgery (Figure 2F through 2H). In addition, improvement in systolic contractility and stroke volume was noted with BRNPs treatment, suggesting improved systolic function (Table S2).

**BRNPs Attenuate Myocardial Damage Via Inhibition of Apoptosis After I/R**

Inhibition of apoptosis is an important target for therapeutic intervention against I/R-induced tissue damage and organ dysfunction. To assess the antiapoptotic effect of BRNPs after I/R injury, we first evaluated the myocardial damage by measuring the infarct size using FluoSpheres and 2,3,5-triphenyltetrazolium chloride staining 24 hours after cardiac I/R. There was a significant increase in the infarct size (non-2,3,5-triphenyltetrazolium chloride–stained myocardium)/area at risk (non-FluoSpheres area) after I/R surgery (Figure 3A and 3B). Consistent with the cardiac functional data, BRNPs significantly reduced the infarct size compared with the vehicle group after I/R surgery. We then used TUNEL staining to quantify cardiac apoptosis. There was a significant increase in the number of apoptotic cells in the heart after cardiac I/R compared with sham-operated hearts (Figure 3C and 3D). Treatment with BRNPs significantly reduced the number of TUNEL-positive cells in the heart compared with the vehicle-treated group after cardiac I/R.

**BRNPs Reduced Inflammation Induced by I/R**

Elevated oxidative stress caused by ROS overproduction is a known factor that causes apoptosis and tissue damage. Therefore, we further evaluated the anti-inflammatory effect of BRNPs by measuring the production of pro-inflammatory cytokines and reactive oxygen species (ROS) after I/R injury. We found that BRNPs significantly reduced the production of pro-inflammatory cytokines and ROS compared with the vehicle group after I/R surgery. These results suggest that BRNPs have a protective effect on myocardial damage via antiapoptotic and anti-inflammatory mechanisms.

Figure 3. Effect of bilirubin nanoparticles (BRNPs) on ischemia/reperfusion (I/R)-induced cardiac apoptosis and infarct size 24 h after cardiac I/R surgery. A and B, Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining of heart tissue section (A) and quantification of the infarct size (B) 24 h after cardiac I/R surgery with or without BRNPs treatment. C and D, Representative TUNEL staining of heart tissue section (C) and the quantification of apoptosis (D) 24 h after cardiac I/R surgery with or without BRNPs treatment. Scale bar=50 µm. *P<0.05 vs sham, †P<0.05 vs PBS I/R; n=5 mice/group (2 female, 3 male) in sham group, 7 mice/group (3 female, 4 male) in I/R group.
damage. To determine whether the beneficial effects of BRNPs treatment is associated with their antioxidant and anti-inflammatory properties during cardiac I/R, we first performed dihydroethidium staining on cryosections of the heart 24 hours after cardiac I/R. There was a significant increase in dihydroethidium fluorescence in vehicle-treated hearts compared with sham-operated hearts (Figure 4A), suggesting a significant overproduction of ROS in the heart after cardiac I/R. BRNPs treatment significantly reduced the dihydroethidium fluorescence in hearts compared with the vehicle-treated group after cardiac I/R.

Previous studies showed that increased nicotinamide adenine dinucleotide phosphate oxidase (NOX) expression level and NOX-dependent ROS production influence several key components in cardiac remodeling, such as apoptosis, contractility, and fibrosis.27 Thus, we measured the level of NOX-2 and NOX-4 mRNA in the hearts after cardiac I/R. The mRNA levels of both NOX-2 and NOX-4 were upregulated in the heart in response to I/R compared with sham operation (Figure 4B through 4D). BRNPs treatment significantly attenuated the mRNA level of NOX-2 compared with vehicle treatment after cardiac I/R surgery. However, there was no statistically significant difference between BRNPs-treated and vehicle-treated mouse hearts after I/R surgery on NOX-4 mRNA expression level (Figure 4B through 4D). This finding suggests that BRNPs treatment attenuates myocardial damage via inhibition of oxidative stress.

In addition, we evaluated the inflammatory response in the heart after cardiac I/R by measuring the mRNA expression of inflammatory markers, MCP-1 (monocyte chemoattractant protein-1), and TNF-α (tumor necrosis factor-α). Both were significantly increased in the heart after cardiac I/R compared with the sham-operated group (Figure 5A through 5C). BRNPs treatment significantly attenuated the increase in TNF-α and MCP-1 mRNA levels compared with the vehicle-treated heart after cardiac I/R. These results indicated that BRNPs can effectively prevent I/R-induced tissue damage by inhibiting apoptosis and inflammation.

**DISCUSSION**

In this study, we showed that BRNPs could specifically target to the injury site in the heart after cardiac I/R. This targeting and ROS-scavenging ability of BRNPs resulted in significantly reduced infarct size after I/R. In addition, cardiac function measured by echocardiography and PV loop showed BRNPs administration significantly attenuated I/R-induced cardiac dysfunction. The mechanism of the BRNPs’ protective effects was most likely because of the antioxidant effect of bilirubin. BRNPs treatment resulted in inhibition of ROS-induced cardiomyocyte apoptosis and inflammation.

Nanoparticle-based therapeutic systems have been examined in the treatment of various diseases because of their ability to effectively target diseased areas.28

---

**Figure 4.** Effect of bilirubin nanoparticles (BRNPs) on ischemia/reperfusion (I/R)-induced reactive oxygen species overproduction 24 h after cardiac I/R surgery.

A, Representative dihydroethidium staining of heart tissue 24 h after cardiac I/R surgery with or without BRNPs treatment. Scale bar=50 µm. B, Representative mRNA levels of nicotinamide adenine dinucleotide phosphate oxidase (NOX)-2 and NOX-4 24 h after cardiac I/R surgery with and without BRNPs treatment. C and D, Quantification of NOX-2 (C) and NOX-4 (D) mRNA levels 24 h after cardiac I/R surgery with or without BRNPs treatment. #P<0.05 vs sham; †P<0.05 vs PBS I/R; n=5 mice/group (2 female, 3 male) in sham group, 7 mice/group (3 female, 4 male) in I/R group. 18S indicates 18S ribosomal RNA.
Previous studies demonstrated that nanoparticle drug delivery system could release drugs specifically to the affected area after cardiac I/R. Recently, different classes of nanoparticles have been developed for targeted drug delivery. However, low biocompatibility, low biodegradability, and potential toxicity caused by their accumulation in nontargeted organs limit the beneficial effects of these nanoparticles, hindering their application in the clinical setting.

Bilirubin is a final metabolite of heme catabolism. Although increased circulating bilirubin levels is considered a sign of liver disease, bilirubin is inversely correlated with many cardiovascular disease risk factors, such as hypertension, type 2 diabetes, metabolic syndrome, and obesity. Free bilirubin and unconjugated bilirubin are effective scavengers of peroxyl radicals against various oxidative stresses. However, their poor solubility can lead to toxic waste deposition in various tissues. Our small-sized polyethylene glycol–modified BRNPs are soluble in physiological conditions. We also found that the antioxidant effect of bilirubin in the form of BRNPs was similar to unconjugated free bilirubin. In addition, BRNPs can be cleared out of the body through the hepatobiliary and renal excretory system, reducing the risk of toxicity when accumulated in nontargeted organs limit the beneficial effects of these nanoparticles, hindering their application in the clinical setting.

Bilirubin is a final metabolite of heme catabolism. Although increased circulating bilirubin levels is considered a sign of liver disease, bilirubin is inversely correlated with many cardiovascular disease risk factors, such as hypertension, type 2 diabetes, metabolic syndrome, and obesity. Free bilirubin and unconjugated bilirubin are effective scavengers of peroxyl radicals against various oxidative stresses. However, their poor solubility can lead to toxic waste deposition in various tissues. Our small-sized polyethylene glycol–modified BRNPs are soluble in physiological conditions. We also found that the antioxidant effect of bilirubin in the form of BRNPs was similar to unconjugated free bilirubin. In addition, BRNPs can be cleared out of the body through the hepatobiliary and renal excretory system, reducing the risk of toxicity when accumulated in nontargeted organs limit the beneficial effects of these nanoparticles, hindering their application in the clinical setting.

Bilirubin is a final metabolite of heme catabolism. Although increased circulating bilirubin levels is considered a sign of liver disease, bilirubin is inversely correlated with many cardiovascular disease risk factors, such as hypertension, type 2 diabetes, metabolic syndrome, and obesity. Free bilirubin and unconjugated bilirubin are effective scavengers of peroxyl radicals against various oxidative stresses. However, their poor solubility can lead to toxic waste deposition in various tissues. Our small-sized polyethylene glycol–modified BRNPs are soluble in physiological conditions. We also found that the antioxidant effect of bilirubin in the form of BRNPs was similar to unconjugated free bilirubin. In addition, BRNPs can be cleared out of the body through the hepatobiliary and renal excretory system, reducing the risk of toxicity when accumulated in nontargeted organs limit the beneficial effects of these nanoparticles, hindering their application in the clinical setting.

Bilirubin is a final metabolite of heme catabolism. Although increased circulating bilirubin levels is considered a sign of liver disease, bilirubin is inversely correlated with many cardiovascular disease risk factors, such as hypertension, type 2 diabetes, metabolic syndrome, and obesity. Free bilirubin and unconjugated bilirubin are effective scavengers of peroxyl radicals against various oxidative stresses. However, their poor solubility can lead to toxic waste deposition in various tissues. Our small-sized polyethylene glycol–modified BRNPs are soluble in physiological conditions. We also found that the antioxidant effect of bilirubin in the form of BRNPs was similar to unconjugated free bilirubin. In addition, BRNPs can be cleared out of the body through the hepatobiliary and renal excretory system, reducing the risk of toxicity when accumulated in nontargeted organs limit the beneficial effects of these nanoparticles, hindering their application in the clinical setting.

Bilirubin is a final metabolite of heme catabolism. Although increased circulating bilirubin levels is considered a sign of liver disease, bilirubin is inversely correlated with many cardiovascular disease risk factors, such as hypertension, type 2 diabetes, metabolic syndrome, and obesity. Free bilirubin and unconjugated bilirubin are effective scavengers of peroxyl radicals against various oxidative stresses. However, their poor solubility can lead to toxic waste deposition in various tissues. Our small-sized polyethylene glycol–modified BRNPs are soluble in physiological conditions. We also found that the antioxidant effect of bilirubin in the form of BRNPs was similar to unconjugated free bilirubin. In addition, BRNPs can be cleared out of the body through the hepatobiliary and renal excretory system, reducing the risk of toxicity when accumulated in nontargeted organs limit the beneficial effects of these nanoparticles, hindering their application in the clinical setting.

Bilirubin is a final metabolite of heme catabolism. Although increased circulating bilirubin levels is considered a sign of liver disease, bilirubin is inversely correlated with many cardiovascular disease risk factors, such as hypertension, type 2 diabetes, metabolic syndrome, and obesity. Free bilirubin and unconjugated bilirubin are effective scavengers of peroxyl radicals against various oxidative stresses. However, their poor solubility can lead to toxic waste deposition in various tissues. Our small-sized polyethylene glycol–modified BRNPs are soluble in physiological conditions. We also found that the antioxidant effect of bilirubin in the form of BRNPs was similar to unconjugated free bilirubin. In addition, BRNPs can be cleared out of the body through the hepatobiliary and renal excretory system, reducing the risk of toxicity when accumulated in nontargeted organs limit the beneficial effects of these nanoparticles, hindering their application in the clinical setting.

Bilirubin is a final metabolite of heme catabolism. Although increased circulating bilirubin levels is considered a sign of liver disease, bilirubin is inversely correlated with many cardiovascular disease risk factors, such as hypertension, type 2 diabetes, metabolic syndrome, and obesity. Free bilirubin and unconjugated bilirubin are effective scavengers of peroxyl radicals against various oxidative stresses. However, their poor solubility can lead to toxic waste deposition in various tissues. Our small-sized polyethylene glycol–modified BRNPs are soluble in physiological conditions. We also found that the antioxidant effect of bilirubin in the form of BRNPs was similar to unconjugated free bilirubin. In addition, BRNPs can be cleared out of the body through the hepatobiliary and renal excretory system, reducing the risk of toxicity when accumulated in nontargeted organs limit the beneficial effects of these nanoparticles, hindering their application in the clinical setting.

Bilirubin is a final metabolite of heme catabolism. Although increased circulating bilirubin levels is considered a sign of liver disease, bilirubin is inversely correlated with many cardiovascular disease risk factors, such as hypertension, type 2 diabetes, metabolic syndrome, and obesity. Free bilirubin and unconjugated bilirubin are effective scavengers of peroxyl radicals against various oxidative stresses. However, their poor solubility can lead to toxic waste deposition in various tissues. Our small-sized polyethylene glycol–modified BRNPs are soluble in physiological conditions. We also found that the antioxidant effect of bilirubin in the form of BRNPs was similar to unconjugated free bilirubin. In addition, BRNPs can be cleared out of the body through the hepatobiliary and renal excretory system, reducing the risk of toxicity when accumulated in nontargeted organs limit the beneficial effects of these nanoparticles, hindering their application in the clinical setting.

Bilirubin is a final metabolite of heme catabolism. Although increased circulating bilirubin levels is considered a sign of liver disease, bilirubin is inversely correlated with many cardiovascular disease risk factors, such as hypertension, type 2 diabetes, metabolic syndrome, and obesity. Free bilirubin and unconjugated bilirubin are effective scavengers of peroxyl radicals against various oxidative stresses. However, their poor solubility can lead to toxic waste deposition in various tissues. Our small-sized polyethylene glycol–modified BRNPs are soluble in physiological conditions. We also found that the antioxidant effect of bilirubin in the form of BRNPs was similar to unconjugated free bilirubin. In addition, BRNPs can be cleared out of the body through the hepatobiliary and renal excretory system, reducing the risk of toxicity when accumulated in nontargeted organs limit the beneficial effects of these nanoparticles, hindering their application in the clinical setting.

Bilirubin is a final metabolite of heme catabolism. Although increased circulating bilirubin levels is considered a sign of liver disease, bilirubin is inversely correlated with many cardiovascular disease risk factors, such as hypertension, type 2 diabetes, metabolic syndrome, and obesity. Free bilirubin and unconjugated bilirubin are effective scavengers of peroxyl radicals against various oxidative stresses. However, their poor solubility can lead to toxic waste deposition in various tissues. Our small-sized polyethylene glycol–modified BRNPs are soluble in physiological conditions. We also found that the antioxidant effect of bilirubin in the form of BRNPs was similar to unconjugated free bilirubin. In addition, BRNPs can be cleared out of the body through the hepatobiliary and renal excretory system, reducing the risk of toxicity when accumulated in nontargeted organs limit the beneficial effects of these nanoparticles, hindering their application in the clinical setting.

Bilirubin is a final metabolite of heme catabolism. Although increased circulating bilirubin levels is considered a sign of liver disease, bilirubin is inversely correlated with many cardiovascular disease risk factors, such as hypertension, type 2 diabetes, metabolic syndrome, and obesity. Free bilirubin and unconjugated bilirubin are effective scavengers of peroxyl radicals against various oxidative stresses. However, their poor solubility can lead to toxic waste deposition in various tissues. Our small-sized polyethylene glycol–modified BRNPs are soluble in physiological conditions. We also found that the antioxidant effect of bilirubin in the form of BRNPs was similar to unconjugated free bilirubin. In addition, BRNPs can be cleared out of the body through the hepatobiliary and renal excretory system, reducing the risk of toxicity when accumulated in nontargeted organs limit the beneficial effects of these nanoparticles, hindering their application in the clinical setting.

Bilirubin is a final metabolite of heme catabolism. Although increased circulating bilirubin levels is considered a sign of liver disease, bilirubin is inversely correlated with many cardiovascular disease risk factors, such as hypertension, type 2 diabetes, metabolic syndrome, and obesity. Free bilirubin and unconjugated bilirubin are effective scavengers of peroxyl radicals against various oxidative stresses. However, their poor solubility can lead to toxic waste deposition in various tissues. Our small-sized polyethylene glycol–modified BRNPs are soluble in physiological conditions. We also found that the antioxidant effect of bilirubin in the form of BRNPs was similar to unconjugated free bilirubin. In addition, BRNPs can be cleared out of the body through the hepatobiliary and renal excretory system, reducing the risk of toxicity when accumulated in nontargeted organs limit the beneficial effects of these nanoparticles, hindering their application in the clinical setting.
reduction of NOX-4. Although it is reasonable to inhibit NOX activities to decrease ROS production during I/R injury, a complete inhibition of the NOX family is likely not favorable, because NOX is also responsible for the physiological production of ROS. A minimal amount of ROS is essential to prevent I/R injury via metabolic adaptations involving HIF-1α–(hypoxia-inducible factor 1-α) and PPAR-α–(peroxisome proliferator-activated receptor-α) dependent mechanisms. Therefore, selective blockage of NOX of BRNPs may be desirable.

It has been shown that intraperitoneal administration of bilirubin could increase plasma levels of bilirubin, but is quickly eliminated from the circulation. In the serum, ~99% of the bilirubin is bound to plasma protein and hence unavailable for intracellular actions. Therefore, it has been suggested that redosing or chemical modification of the molecule would be necessary to maintain a sustained effect. Our BRNPs may be an effective strategy to deliver bilirubin to the targeted sites to increase the efficacy of bilirubin. Specifically, intravenous administration before reperfusion would be more clinically applicable to facilitate prophylactic treatment of individuals that are at risk of myocardial infarction. Because our study was a proof-of-concept study, we did not perform the pharmacokinetics of BRNPs. Of note, we showed that BRNPs preferentially target to the ischemic cardiac tissues. Thus, the blood level may not truly reflect the actual bilirubin concentration at the site of ischemic tissues. Further pharmacokinetic analysis will be needed for the circulating and local concentrations of BRNPs before clinical use.

In conclusion, these findings support the physiological importance of bilirubin in protecting the heart against I/R injury, and suggest the potential of BRNPs to be used as a new therapeutic option for various I/R injury-related diseases.

ARTICLE INFORMATION
Received February 8, 2021; accepted August 18, 2021.

Affiliations
Cardiovascular Institute, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA (W.A., S.B., Q.K., S.S., R.L., Y.C., E.L., P.M.K.); Department of Cardiology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, China (W.A., Y.C.); and Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea (D.Y., S.J.).

Source of Funding
This study was supported in part by grants from the National Institutes of Health (R44DK103389-01, P.M.K.), and American Heart Association Grant in Aid (17GRNT33680101, P.M.K.).

Disclosures
Dr Jon is a coinventor of BRNPs technology and has a patent for the use of BRNPs (Korea Patent 1681299). Dr Jon declares a financial interest in Bilix. This company did not support the aforementioned research and currently has no rights to any technology or intellectual property developed as part of this research. The remaining authors have no disclosures to report.

Supplementary Material
Table S1–S2

REFERENCES
1. Anderson JL, Morrow DA. Acute myocardial infarction. N Engl J Med. 2017;378:2053–2064. doi: 10.1056/NEJMra1609615
2. Arbel Y, Ko DT, Yan AT, Cantor WJ, Bagai A, Koh M, Eberg M, Tan M, Fitchett D, Borgundvaag B, et al. Long-term follow-up of the Trial of Routine Angioplasty and Stenting After Fibroinjury to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Can J Cardiol. 2018;34:736–743. doi: 10.1016/j.cjca.2018.02.005
3. Berg K, Jynge P, Bjerve K, Skarra S, Basu S, Wiseth R. Oxidative stress and inflammatory response during and following coronary interventions for acute myocardial infarction. Free Radic Res. 2005;39:629–636. doi: 10.1080/10715760400820277
4. Yang L, Zhang Y, Zhu M, Zhang Q, Wang X, Wang Y, Zhang J, Li J, Yang L, Liu J, et al. Resveratrol attenuates myocardial ischemia/reperfusion injury through up-regulation of vascular endothelial growth factor B. Free Radic Biol Med. 2016;101:1–9. doi: 10.1016/j.freeradmed.2016.09.016
5. Munzel T, Gori T, Bruno RM, Tadose S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J. 2010;31:2741–2748. doi: 10.1093/eurheartj/eqn396
6. Chung JO, Cho DH, Chung DJ, Chung MY. Physiological serum bilirubin concentrations are inversely associated with the prevalence of cardiovascular autonomic neuropathy in patients with Type 2 diabetes. Diabet Med. 2014;31:185–191. doi: 10.1111/dme.12338
7. Canpolat U, Aytemir K, Yorgun H, Hazirolan T, Kaya EB, Sahiner S, Sunman H, Tokgozoglu L, Kabacgi O, Ato O. Association of serum total bilirubin levels with the severity, extent and subtypes of coronary atherosclerotic plaques detected by coronary CT angiography. Int J Cardiovasc Imaging. 2013;29:1371–1379. doi: 10.1007/s10554-013-0209-7
8. Zhou T, Prather ER, Garrison DE, Zuo L. Interplay between ROS and antioxidants during ischemia-reperfusion injuries in cardiac and skeletal muscle. Int J Mol Sci. 2018;19. doi: 10.3390/ijms19020417
9. McCallum L, Panniyammakal J, Hastie CE, Hewitt J, Patel R, Jones GC, Muir S, Walters M, Sattar N, Dominiczak AF, et al. Longitudinal blood pressure control, long-term mortality, and predictive utility of serum liver enzymes and bilirubin in hypertensive patients. Hypertension. 2015;66:37–43. doi: 10.1161/HYPERTENSIONAHA.114.04915
10. Demirkol S, Baltta S, Celik T, Uluu M, Arslan Z, Canak M, Kucuk U, Ilsoyo A, Barcin C, Demirbas S, et al. Carotid intima media thickness and its association with total bilirubin levels in patients with coronary artery ectasia. Angiology. 2020;71:425–430. doi: 10.1177/0003319712473796
11. Horstfall LJ, Rait G, Walters K, Swallow DM, Pereira SP, Nazareth I, Petersen I. Serum bilirubin and risk of respiratory disease and death. JAMA. 2011;305:691–697. doi: 10.1001/jama.2011.124
12. Vitek L, Jirsa M, Brodanova M, Kalab M, Marecek Z, Danzig V, Novotny P, Petersen I. Serum bilirubin and risk of respiratory disease and death. Atherosclerosis. 2002;160:449–456. doi: 10.1016/S0021-9150(01)00601-3
13. Bakraria B, Du Toit EF, Ashton KJ, Wagner KH, Headrick JP, Bulmer AC. Chronically elevated bilirubin protects from cardiac reperfusion injury in the male Gunn rat. Acta Physiol. 2017;220:481–490. doi: 10.1111/apha.12858
14. Akboga MK, Canpolat U, Sahinarslan A, Alsancak Y, Nurkoc S, Aras D, Aydogdu S, Abaci A. Association of serum total bilirubin level with severity of coronary atherosclerosis is linked to systemic inflammation. Atherosclerosis. 2015;240:110–114. doi: 10.1016/j.atherosclerosis.2015.02.081
15. Bulmer AC, Bakraria B, Du Toit EF, Boon AO, Clark PJ, Powell LW, Wagner KH, Headrick JP. Bilirubin acts as a multipotent guardian of cardiovascular integrity: more than just a radical idea. Am J Physiol Heart Circ Physiol. 2018;315:F429–F447. doi: 10.1152/ajpheart.00417.2017
16. Jorgensen ME, Torp-Pedersen C, Finer N, Caterson I, James WP, Legler UF, Andersson C. Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT
Bilirubin Nanoparticles in I/R Injury

10.1161/JAHA.121.021212

Ai et al. Bilirubin Nanoparticles in I/R Injury

2012;10:e021212. DOI: 10.1161/JAHA.121.021212
SUPPLEMENTAL MATERIAL
Table S1. Echocardiographic analyses after cardiac I/R with or without BRNP treatment in mice.

|                | Sham                      | I/R                      |
|----------------|---------------------------|--------------------------|
|                | PBS          | BRNP(10)     | BRNP(30)     | PBS          | BRNP(10)     | BRNP(30)     |
| AWd (mm)       | 0.77±0.03    | 0.77±0.04    | 0.73±0.02    | 0.63±0.05*   | 0.81±0.04†   | 0.79±0.03†   |
| PWd (mm)       | 0.81±0.03    | 0.79±0.05    | 0.84±0.05    | 0.78±0.03    | 0.76±0.03    | 0.79±0.04    |
| LVDd (mm)      | 3.74±0.11    | 3.57±0.08    | 3.41±0.15    | 4.00±0.12    | 3.77±0.06    | 3.76±0.10    |
| LVDs (mm)      | 2.46±0.09    | 2.41±0.11    | 2.33±0.11    | 3.11±0.13*   | 2.60±0.07    | 2.35±0.11†   |
| EF (%)         | 64.0±1.6     | 61.8±2.5     | 62.7±2.9     | 44.8±3.9*    | 59.4±1.0†    | 68.5±2.3†    |
| FS (%)         | 34.3±1.4     | 32.7±1.9     | 35.6±1.6     | 22.1±2.5*    | 28.7±0.9†    | 31.8±1.7†    |

HR=heart rate, AWd=anterior wall thickness in diastole, PWd=posterior wall thickness in diastole, LVDd=left ventricular dimension in diastole, LVDs=left ventricular dimension in systole, FS=fractional shortening. Results are presented as mean±SEM. *P < 0.05 vs. Sham; †P < 0.05 vs. PBS I/R; n=5 mice/group (2 female, 3 male) in sham group, 7 mice/group (3 female, 4 male) in I/R group.
Table S2. Left ventricular pressure-volume hemodynamic measurements after cardiac I/R with or without BRNP treatment in mice.

|                     | Sham                  | I/R                  |
|---------------------|-----------------------|----------------------|
|                     | PBS       | BRNP(10) | BRNP(30) | PBS       | BRNP(10) | BRNP(30) |
| HR (beat/min)       | 484±13.6  | 497±8.6  | 488±14.8 | 433±6.4  | 476±5.8  | 485±10.7 |
| LVSP (mmHg)         | 121.5±2.3 | 119.0±2.6 | 119.9±3.8 | 108.4±2.3* | 115.1±1.8 | 121.1±2.0† |
| LVEDP (mmHg)        | 3.0±0.41  | 2.7±0.45  | 2.8±0.74 | 4.1±0.70* | 3.4±0.44  | 2.9±0.36† |
| dP/dt<sub>max</sub> (mmHg/s) | 12547±452 | 12600±477 | 12564±467 | 8760±479* | 10731±283† | 12470±364† |
| dP/dt<sub>min</sub> (mmHg/s) | -8032±252 | -8264±150 | -8250±135 | -7869±248 | -7915±274 | -7980±203 |
| SV (μl)             | 16.4±0.94 | 15.6±1.06 | 16.2±1.54 | 9.6±0.68* | 12.8±0.83 | 15.1±0.84† |
| SW (mmHgxμl)        | 2128±89  | 2033±102 | 2086±164 | 1194±69* | 1563±73† | 1959±76† |
| CO (mL/min)         | 7.9±0.34 | 7.7±0.38  | 7.9±0.56 | 4.2±0.29* | 6.1±0.28† | 7.2±0.30† |

LVEDP, left ventricular end diastolic pressure; LVSP, left ventricular systolic pressure, dP/dt<sub>max</sub> and dP/dt<sub>min</sub>, maximum and minimum first derivative of ventricular pressure with respect to time; SV, stroke volume; SW, stroke work; CO, cardiac output. *P < 0.05, vs. Sham; †P < 0.05, vs. PBS I/R; n=5 mice/group (2 female, 3 male) in sham group, 7 mice/group (3 female, 4 male) in I/R group.